Estrogen metabolism by cytochrome P450 1B1 modulates the hypertensive effect of angiotensin II in female mice

Hypertension

Volumn 64, Issue 1, 2014, Pages 134-140

  Jennings, Brett L ^a   George, L Watson ^a   Pingili, Ajeeth K ^a   Khan, Nayaab S ^a   Estes, Anne M ^a   Fang, Xiao R ^a   Gonzalez, Frank J ^b   Malik, Kafait U ^a  

^a UNIVERSITY OF TENNESSEE COLLEGE OF MEDICINE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

2 methoxyestradiol; cytochrome P450 1B1; hypertension; ovariectomy; oxidative stress

Indexed keywords

2 HYDROXYESTRADIOL; 2 METHOXYESTRADIOL; 2,3',4,5' TETRAMETHOXYSTILBENE; 4 HYDROXYESTRADIOL; ANGIOTENSIN II; CATECHOL METHYLTRANSFERASE; CYTOCHROME P450 1B1; ESTRADIOL; ESTROGEN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; STILBENE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL REACTIVITY; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ESTROGEN METABOLISM; FEMALE; HYPERTENSION; MOUSE; NONHUMAN; OVARIECTOMY; OXIDATIVE STRESS; PRIORITY JOURNAL; SEX DIFFERENCE; SIGNAL TRANSDUCTION; SYSTOLIC BLOOD PRESSURE;

2-METHOXYESTRADIOL; CYTOCHROME P450 1B1; HYPERTENSION; OVARIECTOMY; OXIDATIVE STRESS;

ANGIOTENSIN II; ANIMALS; ARYL HYDROCARBON HYDROXYLASES; BLOOD PRESSURE; ESTRADIOL; FEMALE; HEART; HYPERTENSION; MICE; MICE, KNOCKOUT; MYOCARDIUM; OXIDATIVE STRESS;

EID: 84902549825     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.114.03275     Document Type: Article

References (57)

1. Messerli FH, Garavaglia GE, Schmieder RE, Sundgaard-Riise K, Nunez BD, Amodeo C. Disparate cardiovascular findings in men and women with essential hypertension. Ann Intern Med. 1987;107: 158-161.
2. Stampfer MJ, Colditz GA, Willett WC, Manson JE, Rosner B, Speizer FE, Hennekens CH. Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. N Engl J Med. 1991;325: 756-762.
3. Burt VL, Whelton P, Roccella EJ, Brown C, Cutler JA, Higgins M, Horan MJ, Labarthe D. Prevalence of hypertension in the US adult population. Results from the Third National Health and Nutrition Examination Survey, 1988-1991. Hypertension. 1995;25: 305-313.
4. Staessen J, Bulpitt CJ, Fagard R, Lijnen P, Amery A. The influence of menopause on blood pressure. J Hum Hypertens. 1989;3: 427-433.
5. Dubey RK, Oparil S, Imthurn B, Jackson EK. Sex hormones and hypertension. Cardiovasc Res. 2002;53: 688-708.
6. Xue B, Johnson AK, Hay M. Sex differences in angiotensin II-induced hypertension. Braz J Med Biol Res. 2007;40: 727-734.
7. Jennings BL, Sahan-Firat S, Estes AM, Das K, Farjana N, Fang XR, Gonzalez FJ, Malik KU. Cytochrome P450 1B1 contributes to angiotensin II-induced hypertension and associated pathophysiology. Hypertension. 2010;56: 667-674.
8. Jennings BL, Anderson LJ, Estes AM, Yaghini FA, Fang XR, Porter J, Gonzalez FJ, Campbell WB, Malik KU. Cytochrome P450 1B1 contributes to renal dysfunction and damage caused by angiotensin II in mice. Hypertension. 2012;59: 348-354.
9. Watanabe K, Yoshizawa I. Tissue distribution of estradiol 17- sulfate 2- and 4-hydroxylation enzymes in the rat. J Pharmacobiodyn. 1987;10: 302-308.
10. Badawi AF, Cavalieri EL, Rogan EG. Role of human cytochrome P450 1A1, 1A2, 1B1, and 3A4 in the 2-, 4-, and 16α-hydroxylation of 17β-estradiol. Metabolism. 2001;50: 1001-1003.
11. Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT. Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003;144: 3382-3398.
12. Rahman M, Sutter CH, Emmert GL, Sutter TR. Regioselective 2- hydroxylation of 17β-estradiol by rat cytochrome P4501B1. Toxicol Appl Pharmacol. 2006;216: 469-478.
13. Kurtz TW, Griffin KA, Bidani AK, Davisson RL, Hall JE. Recommendations for blood pressure measurement in humans and experimental animals. Part 2: blood pressure measurement in experimental animals. A statement for professionals from the subcommittee of professional and public education of the American Heart Association Council on High Blood Pressure Research. Hypertension. 2005;45: 299-310.
14. Chun YJ, Kim S, Kim D, Lee SK, Guengerich FP. A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis. Cancer Res. 2001;61: 8164-8170.
15. Mehta PK, Griendling KK. Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. Am J Physiol Cell Physiol. 2007;292:C82-C97. (Pubitemid 46127306)
16. Rajagopalan S, Kurz S, Münzel T, Tarpey M, Freeman BA, Griendling KK, Harrison DG. Angiotensin II-mediated hypertension in the rat increases vascular superoxide production via membrane NADH/NADPH oxidase activation. Contribution to alterations of vasomotor tone. J Clin Invest. 1996;97: 1916-1923.
17. Harrison DG, Gongora MC. Oxidative stress and hypertension. Med Clin North Am. 2009;93: 621-635.
18. Nistala R, Whaley-Connell A, Sowers Jr. Redox control of renal function and hypertension. Antioxid Redox Signal. 2008;10: 2047-2089.
19. Paravicini TM, Touyz RM. Redox signaling in hypertension. Cardiovasc Res. 2006;71: 247-258.
20. Xue B, Pamidimukkala J, Hay M. Sex differences in the development of angiotensin II-induced hypertension in conscious mice. Am J Physiol Heart Circ Physiol. 2005;288:H2177-H2184. (Pubitemid 40604103)
21. Sahan-Firat S, Jennings BL, Yaghini FA, Song CY, Estes AM, Fang XR, Farjana N, Khan AI, Malik KU. 2, 3', 4, 5'-Tetramethoxystilbene prevents deoxycorticosterone-salt-induced hypertension: contribution of cytochrome P-450 1B1. Am J Physiol Heart Circ Physiol. 2010;299:H1891-H1901.
22. Jennings BL, Estes AM, Anderson LJ, Fang XR, Yaghini FA, Fan Z, Gonzalez FJ, Campbell WB, Malik KU. Cytochrome P450 1B1 gene disruption minimizes deoxycorticosterone acetate-salt-induced hypertension and associated cardiac dysfunction and renal damage in mice. Hypertension. 2012;60: 1510-1516.
23. Choudhary D, Jansson I, Stoilov I, Sarfarazi M, Schenkman JB. Metabolism of retinoids and arachidonic acid by human and mouse cytochrome P450 1b1. Drug Metab Dispos. 2004;32: 840-847.
24. Ma X, Idle JR, Krausz KW, Gonzalez FJ. Metabolism of melatonin by human cytochromes p450. Drug Metab Dispos. 2005;33: 489-494.
25. Hayes CL, Spink DC, Spink BC, Cao JQ, Walker NJ, Sutter TR. 17 beta- estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc Natl Acad Sci USA. 1996;93: 9776-9781.
26. Tsuchiya Y, Nakajima M, Yokoi T. Cytochrome P450-mediated metabolism of estrogens and its regulation in human. Cancer Lett. 2005;227: 115-124.
27. Sissung TM, Price DK, Sparreboom A, Figg WD. Pharmacogenetics and regulation of human cytochrome P450 1B1: implications in hormone- mediated tumor metabolism and a novel target for therapeutic intervention. Mol Cancer Res. 2006;4: 135-150.
28. Liehr JG, Ricci MJ. 4-Hydroxylation of estrogens as marker of human mammary tumors. Proc Natl Acad Sci USA. 1996;93: 3294-3296.
29. Jefcoate CR, Liehr JG, Santen RJ, Sutter TR, Yager JD, Yue W, Santner SJ, Tekmal R, Demers L, Pauley R, Naftolin F, Mor G, Berstein L. Tissue- specific synthesis and oxidative metabolism of estrogens. J Natl Cancer Inst Monogr. 2000;27: 95-112.
30. Nishida CR, Everett S, Ortiz de Montellano PR. Specificity determinants of CYP1B1 estradiol hydroxylation. Mol Pharmacol. 2013;84: 451-458.
31. Dubey RK, Gillespie DG, Zacharia LC, Barchiesi F, Imthurn B, Jackson EK. CYP450- and COMT-derived estradiol metabolites inhibit activity of human coronary artery SMCs. Hypertension. 2003;41(3 Pt 2): 807-813.
32. Zacharia LC, Dubey RK, Mi Z, Jackson EK. Methylation of 2-hydroxyestradiol in isolated organs. Hypertension. 2003;42: 82-87.
33. Barchiesi F, Jackson EK, Gillespie DG, Zacharia LC, Fingerle J, Dubey RK. Methoxyestradiols mediate estradiol-induced antimitogenesis in human aortic SMCs. Hypertension. 2002;39: 874-879.
34. Spink DC, Eugster HP, Lincoln DW 2nd, Schuetz JD, Schuetz EG, Johnson JA, Kaminsky LS, Gierthy JF. 17 beta-estradiol hydroxylation catalyzed by human cytochrome P450 1A1: a comparison of the activities induced by 2, 3, 7, 8-tetrachlorodibenzo-p-dioxin in MCF-7 cells with those from heterologous expression of the cDNA. Arch Biochem Biophys. 1992;293: 342-348.
35. Badawi AF, Cavalieri EL, Rogan EG. Role of human cytochrome P450 1A1, 1A2, 1B1, and 3A4 in the 2-, 4-, and 16α-hydroxylation of 17β-estradiol. Metabolism. 2001;50: 1001-1003.
36. Zacharia LC, Gogos JA, Karayiorgou M, Jackson EK, Gillespie DG, Barchiesi F, Dubey RK. Methoxyestradiols mediate the antimitogenic effects of 17beta-estradiol: direct evidence from catechol- O-methyltransferase-knockout mice. Circulation. 2003;108: 2974-2978.
37. Dubey RK, Jackson EK. Potential vascular actions of 2-methoxyestradiol. Trends Endocrinol Metab. 2009;20: 374-379.
38. Yang S, Yao B, Zhou Y, Yin H, Zhang MZ, Harris RC. Intrarenal dopamine modulates progressive angiotensin II-mediated renal injury. Am J Physiol Renal Physiol. 2012;302:F742-F749.
39. Bonacasa B, Sanchez ML, Rodriguez F, Lopez B, Quesada T, Fenoy FJ, Hernández I. 2-Methoxyestradiol attenuates hypertension and coronary vascular remodeling in spontaneously hypertensive rats. Maturitas. 2008;61: 310-316.
40. Yuan W, Yu Y, Li J, Singh P, Li D, Gui Y, Zheng XL. Estrogen metabolite 2-methoxyestradiol prevents hypertension in deoxycorticosterone acetate- salt rats. Cardiovasc Drugs Ther. 2013;27: 17-22.
41. Nickenig G, Bäumer AT, Grohè C, Kahlert S, Strehlow K, Rosenkranz S, Stäblein A, Beckers F, Smits JF, Daemen MJ, Vetter H, Böhm M. Estrogen modulates AT1 receptor gene expression in vitro and in vivo. Circulation. 1998;97: 2197-2201.
42. Brosnihan KB, Senanayake PS, Li P, Ferrario CM. Bi-directional actions of estrogen on the renin-angiotensin system. Braz J Med Biol Res. 1999;32: 373-381.
43. Sampson AK, Moritz KM, Jones ES, Flower RL, Widdop RE, Denton KM. Enhanced angiotensin II type 2 receptor mechanisms mediate decreases in arterial pressure attributable to chronic low-dose angiotensin II in female rats. Hypertension. 2008;52: 666-671.
44. Sullivan JC, Bhatia K, Yamamoto T, Elmarakby AA. Angiotensin (1-7) receptor antagonism equalizes angiotensin II-induced hypertension in male and female spontaneously hypertensive rats. Hypertension. 2010;56: 658-666.
45. Koganti S, Snyder R, Gumaste U, Karamyan VT, Thekkumkara T. 2-methoxyestradiol binding of GPR30 down-regulates angiotensin AT(1) receptor. Eur J Pharmacol. 2014;723: 131-140.
46. Lopez-Ruiz A, Sartori-Valinotti J, Yanes LL, Iliescu R, Reckelhoff JF. Sex differences in control of blood pressure: role of oxidative stress in hypertension in females. Am J Physiol Heart Circ Physiol. 2008;295:H466-H474.
47. Strehlow K, Rotter S, Wassmann S, Adam O, Grohé C, Laufs K, Böhm M, Nickenig G. Modulation of antioxidant enzyme expression and function by estrogen. Circ Res. 2003;93: 170-177.
48. Gragasin FS, Xu Y, Arenas IA, Kainth N, Davidge ST. Estrogen reduces angiotensin II-induced nitric oxide synthase and NAD(P)H oxidase expression in endothelial cells. Arterioscler Thromb Vasc Biol. 2003;23: 38-44.
49. Zimmerman MC, Lazartigues E, Lang JA, Sinnayah P, Ahmad IM, Spitz DR, Davisson RL. Superoxide mediates the actions of angiotensin II in the central nervous system. Circ Res. 2002;91: 1038-1045.
50. Xue B, Badaue-Passos D Jr, Guo F, Gomez-Sanchez CE, Hay M, Johnson AK. Sex differences and central protective effect of 17beta-estradiol in the development of aldosterone/NaCl-induced hypertension. Am J Physiol Heart Circ Physiol. 2009;296:H1577-H1585.
51. Xue B, Zhang Z, Beltz TG, Johnson RF, Guo F, Hay M, Johnson AK. Estrogen receptor-β in the paraventricular nucleus and rostroventrolateral medulla plays an essential protective role in aldosterone/salt-induced hypertension in female rats. Hypertension. 2013;61: 1255-1262.
52. Li R, Shen Y. Estrogen and brain: synthesis, function and diseases. Front Biosci. 2005;10: 257-267.
53. Muskhelishvili L, Thompson PA, Kusewitt DF, Wang C, Kadlubar FF. In situ hybridization and immunohistochemical analysis of cytochrome P450 1B1 expression in human normal tissues. J Histochem Cytochem. 2001;49: 229-236.
54. Guzik TJ, Hoch NE, Brown KA, McCann LA, Rahman A, Dikalov S, Goronzy J, Weyand C, Harrison DG. Role of the T cell in the genesis of angiotensin II induced hypertension and vascular dysfunction. J Exp Med. 2007;204: 2449-2460.
55. Barhoumi T, Kasal DA, Li MW, Shbat L, Laurant P, Neves MF, Paradis P, Schiffrin EL. T regulatory lymphocytes prevent angiotensin II-induced hypertension and vascular injury. Hypertension. 2011;57: 469-476.
56. Cunningham M, Gilkeson G. Estrogen receptors in immunity and autoimmunity. Clin Rev Allergy Immunol. 2011;40: 66-73.
57. Shand FH, Langenbach SY, Keenan CR, Ma SP, Wheaton BJ, Schuliga MJ, Ziogas J, Stewart AG. In vitro and in vivo evidence for anti- inflammatory properties of 2-methoxyestradiol. J Pharmacol Exp Ther. 2011;336: 962-972.